Athersys Inc  (ATHX)
Other Ticker:  
Price: $0.0135 $-0.01 -33.498%
Day's High: $0.0212 Week Perf: -36.02 %
Day's Low: $ 0.01 30 Day Perf: -22.86 %
Volume (M): 6,463 52 Wk High: $ 0.96
Volume (M$): $ 87 52 Wk Avg: $0.35
Open: $0.02 52 Wk Low: $0.01

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 25
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0

Athersys Inc
Athersys Inc is a biotechnology company founded in 1995 and based in Cleveland, Ohio. The company specializes in developing regenerative medicine therapies, focusing on a novel stem cell platform called MultiStem. Athersys is primarily focused on developing treatments for conditions such as ischemic stroke, acute respiratory distress syndrome, and trauma.

The MultiStem platform involves the discovery and development of adult-derived off-the-shelf stem cell therapies. These therapies can be administered to patients without the need for matching or immune suppression, which makes them more accessible and potentially easier to implement in clinical settings.

Athersys has conducted numerous preclinical and clinical trials to evaluate the safety and effectiveness of its regenerative medicine therapies. The company has collaborations with various academic institutions, government agencies, and industry partners to further research and development efforts.

The company's key product candidates include MultiStem for treating ischemic stroke, acute myocardial infarction, and inflammatory bowel disease. Athersys has also explored the application of MultiStem in treating COVID-19-related lung injury.

Athersys Inc is driven by a mission to develop innovative therapies to improve patient outcomes and address significant unmet medical needs. The company continues to pursue research, clinical trials, and partnerships to advance its regenerative medicine pipeline and bring potential treatments to market.

   Company Address: 3201 Carnegie Avenue Cleveland 44115 OH
   Company Phone Number: 431-9900   Stock Exchange / Ticker: ATHX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Athersys Inc

Lackluster Revenue Plagues Athersys Inc Throughout Fiscal Year 2023, Raising Concerns of Financial Stability

Athersys Inc: A Disappointing Fiscal Year 2023 Closes with Alarming Results
Athersys Inc, the leading biotechnology company, recently released its fiscal year 2023 financial results, and the numbers are nothing short of concerning. The company reported a decrease in its loss per share, which may initially seem like an improvement. However, when compared to the prior year, the decrease is quite insignificant, and the company continues to suffer from substantial losses. This downward spiral raises serious doubts about the company's ability to turn its fortunes around.
For the fiscal year ending on September 30, 2023, Athersys Inc reported a loss per share of $-0.15, compared to $-1.15 in the previous year. While this appears to be a positive change, it fails to paint an accurate picture of the company's financial health. In reality, the decrease in losses is nominal, and the company remains far from profitability.

Athersys Inc

Athersys Inc's Financials: Unfavorable Q2 2023 with a Loss of $-0.62 per Share

Athersys Inc, a biotechnology company specializing in regenerative medicine, recently released its financial results for the April to June 30, 2023, financial period. The numbers showed a significant loss, with a decrease in revenue and a higher net loss compared to the previous year.
During the mentioned financial period, Athersys Inc incurred a loss of $0.62 per share, as opposed to a loss of $90.00 per share in the same quarter of the previous year. This is also a bigger loss compared to the previous quarter's loss of $0.43 per share. The company's revenue took a sharp hit, plummeting by 97.884% to $0.05 million from $2.32 million in the same quarter a year prior and sequentially from $0.00 million. Athersys Inc realized a net loss of $12.924 million for the period, highlighting the company's financial challenges.

Athersys Inc

Concerns Grow as Athersys Inc Struggles with Revenue Generation, Accumulates Significant Shortfalls, and Lags Behind Competitors in Receivables Turnover Ratio for Q1 2023

As we look at Athersys Inc's recent financial performance, it is concerning to see that the company is struggling to generate revenue and is instead racking up significant shortfalls. While it is positive to see that the company's ability to collect its outstanding accounts receivable from its corporate clients has improved in the first quarter of 2023 to a ratio of 3.59, which is above the company average, this cannot be seen as a clear sign of a healthy business climate.
In fact, when compared to other companies in the Healthcare sector, it appears that Athersys Inc is lagging behind in its receivables turnover ratio. This should raise a red flag for investors who are considering investing in the company. It suggests that there may be internal issues with how the company is managing its finances, which could ultimately lead to further negative financial performance.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com